Advancing Transcatheter Valve Replacement for Severe Aortic Regurgitation: Innovations in Devices and Multi-Modality ImagingJulien Dreyfus, MD, PhD1; David Messika-Zeitoun, MD, PhD21: Cardiology Department, Centre Cardiologique du Nord, 32-36 rue des moulins gémeaux, 93200 Saint-Denis, France2: Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, CanadaWord Count : 912 wordsAddress for correspondence :Julien Dreyfus, Department of Cardiology, Centre Cardiologique du Nord, Saint-Denis, France. Tel: +33149334803, Fax: +33149334143, E-mail: [email protected] patients with severe symptomatic aortic regurgitation (AR) who are deemed at high surgical risk, off-label use of transcatheter aortic valve replacement (TAVR) is increasingly performed. However, the rate of complications is high in this subset, including migration, paravalvular regurgitation, pacemaker implantation, stroke, bleeding, vascular complication, acute renal failure, surgical conversion and mortality.(1)In this issue of Echocardiography , Hu et al (ref) present their findings on 70 patients (56% of males, mean age=74±8 years) with severe symptomatic AR (all in NYHA functional class III or IV) on native or bioprosthetic valves who underwent a TAVR using the Vita-Flow valves (Microport), a novel self-expanding valve (Figure). The population was divided into two groups: group A consisted of 40 patients with aortic root dilatation or valve prolapse and no valvular calcifications, while group B comprised 30 patients with aortic valve degeneration and/or mild senile calcifications (Agatston score ranging from 0 to 100). All interventions were performed under general anesthesia, with procedural guidance provided by both fluoroscopy and real-time three-dimensional echocardiography. A comprehensive pre-procedural assessment of the anatomy was conducted using both transesophageal echocardiography (TEE) and computed tomography (MSCT) and dedicated software. The study focuses on the utility of echocardiography in the pre-procedural screening, intra-procedural monitoring, and 30-day post-procedural follow-up, while also identifying potential predictors for post-procedural complications.The main results from the study can be summarized as follow:Multimodality imaging analysis demonstrated significant concordance between TEE and MSCT especially in the assessment of the annulus and aorta dimensions, as well as left and right coronary artery height, enabling accurate device sizing.The procedural success rate was high (96%) and there were no deaths at 30 days.Multiple underlying mechanisms of AR were successfully treated.Mild peri-valvular leakage was observed in 16% of cases but no moderate or greater peri-valvular leakage was reported.Incidence of significant complications was low, with 3% experiencing iliac artery dissection, 4% encountering stroke, and 3% developing acute renal insufficiency within 30 days post-procedure. No migration was reported.A noteworthy 22% of patients required new pacemaker implantation due to complete atrioventricular block, with a median implantation time of 6 days with right bundle branch block as the only independent predictor.Procedural success correlated with a positive left ventricular and atrial remodeling at 30 days (reductions in left atrial and left ventricular diameters, and improvement of the left ventricular ejection fraction).The main limitations of this study include its retrospective single-center design, small sample size (although relatively large for a single center), mix of TAVR on native valves and valve-in-valve procedures, and a short follow-up period.A significant proportion of patients with surgical indications for severe AR are not referred, often due to high surgical risk or comorbidities(2,3). Transcatheter treatment of AR is currently on the rise but is much more challenging than for aortic stenosis, notably due to the absence of calcifications.TAVR is currently mostly performed using prostheses developed for aortic stenosis. A recent multicenter registry (PANTHEON) including 201 patients treated with commercially available devices (self-expandable and balloon expendable valves developed for AS) showed that with improvements in TAVR devices, in experienced centers and in selected patients, satisfactory outcomes can be achieved in a majority of patients, but that complications rates remained high (12% of embolization or migration at 1 month and 10% of moderate or greater residual leakage), regardless of prosthesis type. Critically, these complications were associated with high mortality or hospitalization for heart failure rates at 1 year (approximately 25%). Rates of permanent pacemaker implantation were also high (approximately 22%), often associated with device oversizing.(1)Several devices designed for the management of AR are currently available or under evaluation. Presently, the JenaValve Trilogy system (JenaValve Technology) is the only dedicated device to have received Conformité Européenne (CE) mark approval for the transcatheter treatment of patients with AR. A recent multicenter registry, comprising 58 consecutive patients from 6 centers across Germany, demonstrated excellent outcomes with a 98% implantation success rate, the absence of moderate or severe paravalvular regurgitation, a 30-day mortality rate of 1.7%, and a 19.6% rate of new permanent pacemaker implantation.(4) The Jena-Valve ALIGN-AR Pivotal Trial (NCT04415047) included 177 patients with 91% of procedures performed under general anesthesia. The trial yielded a procedural success rate of 95%, with 3% of patients necessitating subsequent surgery. Only 0.6% experienced moderate or severe paravalvular regurgitation, and 30-day mortality rate was 2.2%. Additionally, 24% of patients received new pacemaker implantation, a rate that tended to decrease with experience, particularly with refined strategies for device sizing and positioning.The J-Valve (JC Medical), specifically designed for the treatment of patients with AR, is another alternative. A recent study including 27 patients for compassionate use found a procedural success rate of 81% overall and 100% in the last 15 cases, with no patient having residual AR of moderate or greater degree at 30 days and a 13% rate of new pacemaker implantation.(5)In conclusion, there is a genuine enthusiasm for transcatheter AR management, driven by both industry innovation and clinical demand. Dedicated devices seem to perform better than devices commercially used for aortic stenosis, but pacemaker implantation rate remains high. Multimodal imaging plays a pivotal role in patient and device selection, procedural guidance, and follow-up. Although echocardiography seems accurate, as for aortic stenosis, MSCT will remain the method of choice for pre-intervention procedural planning. As the landscape rapidly evolves, refining patient selection, procedural techniques, and postprocedural care will be paramount to ensuring optimal outcomes in this challenging patient population.

Strain imaging as a tool to engage in unravelling the secrets of cardiac motion in health and disease has opened a new horizon in the field of clinical cardiology beyond the standard algorithm for quantification of left ventricular function and dysfunction. As such, the wider application of strain can probably be compared with the ubiquitous application of the incretin molecule, glucagon like peptide 1 receptor agonist (GLP 1RA) first applied to manage type 2 diabetes, that is now indicated in many different conditions like obesity, heart failure, and Alzheimer’s disease! This commentary would focus on the role of automated strain imaging in heart failure, aortic stenosis, cardiac amyloidosis, atrial fibrillation, left atrial, and right ventricular strain, on a 2-dimensional domain of spacetime navigated, to some extent, by AI. This commentary thus argues that automated strain imaging is becoming an essential tool for comprehensive cardiac assessment across various conditions.

THE ADDED VALUE OF LEFT ATRIAL STRAIN IN CANCER-THERAPY-RELATED CARDIAC DYSFUNCTIONByLaura Romero, MD and Michele Nanna, MDAlbert Einstein Coll of Med/ Cardiac Care and Vascular Medicine, Bronx, NYCorrespondence:Michele Nanna, MD,Associate Professor of Medicine, Albert Einstein College of Medicine/ Cardiac Care and Vascular Medicine1461 Astor Ave, Bronx, NY 10469, USAEmail: [email protected] cardiac dysfunction (CTRCD) is an undesirable side effect of chemotherapy that occurs in approximately 10% of the patients [1]. Targeting early detection and advances in treatment increases cancer survivors [2]. The American Society of Echocardiography and the European Association of Cardiovascular Imaging guidelines recommend the use of Speckle-Tracking-derived LV Global Longitudinal Strain (LV-GLS) as a more objective and accurate method to identify subclinical LV deterioration in patient undergoing chemotherapy [3].In cancer patients, assessment of Left Atrium (LA) function by Speckle Tracking has emerged as a potential tool for predicting CTRCD and its associated morbid arrhythmias such as atrial fibrillation (AF), a frequent complication in this patient population [4-6].Early research work used volumetric approaches to derive LA function parameters. Volumetric parameters are widely used in standard clinical practice and current guidelines assigns prognostic value to end-systolic LA volume in patients with suspected LV diastolic dysfunction [3]. The relationship between LV filling and volumetric parameters is not linear and reduction in LV filling pressures reduces but rarely normalizes LA volumes. LA functional parameters, as measured by novel methods of deformation analysis, more reliably detect reductions in LV filling independent of LA volumes changes [7]. Speckle tracking echocardiography–derived analysis of LA strain provides quantitative parameters for all phases of LA function (reservoir, conduit, and booster pump) and carries similar prognostic significance to that provided by volumetric approaches, in different pathological conditions including cancer patients[5,8].Knowing the impact that LA functions has in detecting CTRCD the study by Lassen and colleagues has tested LA strain in the evaluation of CTRCD as a tool for early detection of myocardial damage induced by chemotherapy [9].In this retrospective cohort study a total of 170 women with HER2+ breast cancer (stage I-IV) undergoing treatment with trastuzumab were studied at baseline, 3 months into treatment and 1 year since treatment initiation. Of note, 77 (45.3%) of participants had prior exposure to anthracycline. Also of note, during the 1- year follow-up, 23 (13.5%) patients had trastuzumab held or stopped for either a decline in Left Ventricular Ejection Fraction (LVEF) in 82.6% of cases or other non-cardiac reasons in the remaining cases.A total of 36 patients developed CTRCD during follow-up. At 3-month follow-up, CTRCD patients had lower LVEF, LV-GLS, LA reservoir strain (LA εres), and LA conduit strain rate (LAεcon-sr) compared to patients that did not develop CTRCD. In the 36 patients developing CTRCD, there was a decline in LVEF from baseline to 3-months follow-up with partial recovery at 1-year follow- up. LV-GLS also declined at 3 months, however, contrary to LVEF a recovery did not occur at 1 year follow up. In the 134 patients who did not develop CTRCD during follow-up, LA Volume Index increased from baseline to 3-month follow-up and then modestly recovered at 1-year. LA strain parameters also declined during follow-up but to a lesser degree than in the CTRCD group suggesting its value as a more sensitive parameters of subtle functional changes. This study is one of the largest studies in patients with breast cancer that has assessed changes in LA strain parameters following treatment with transtuzumab.The new information provided by Lassen et al. is in demonstrating that cancer and its treatment with Transtuzumab may negatively affect atrial function and that measurements of LA strain can detect functional changes related to cardiotoxic effects of chemotherapy. Other studies also support the fact that cancer and chemotherapy can modified LA function earlier than LV function. For example, Laufer-Perl et al. identified that cancer itself caused LA εres to be 17% lower with a further 10% relative reduction in LA εres or a decrease in LA εres below 35% in half of a population of patients undergoing chemotherapy with anthracycline. [10]. Park et al. demonstrated that while both LA εres and LV-GLS were early markers in the detection of CTRCD, LA εres reduction was more sensitive and specific than LV-GLS in predicting CTRCD [6]. Similar abnormalities in LA function were demonstrated by Tadic et al. who showed that LA reservoir and conduit function were reduced, while booster pump function was increased in cancer patients [11]. Combined with the observation by Laufer- Perl and colleagues, this raises the question as to whether LV dysfunction is only the consequence of anti- cancer therapy or if cancer itself leads to abnormalities in function. Thus, both the pathology and the therapy for that pathology can lead to LA functional impairment, which is associated with a higher risk of AF, a frequent arrhythmia in cancer patients with an impact on prognosis [4, 12].Several limitations should be noted. CTRCD is a serious complication of anticancer therapy that can beclassified into Type I exemplified by anthracyline- induced cardiac dysfunction characterized by irreversible myocardial damage due to cumulative administered dose and type II exemplified bytrastuzumab- induced cardiac dysfunction that is dose independent and reversible. The mechanism of cardiac toxicity in both types is not well defined. Current ACC/AHA guidelines recommend that patients who develop Heart Failure (HF) while receiving potentially cardiotoxic therapies should have these therapies discontinued while a diagnostic workup is undertaken to ascertain the cause of HF [12, 13]. These guidelines acknowledge that, particularly in patients receiving trastuzumab, asymptomatic decreases in LVEF can occur in approximately 10% of patients, yet, a high recovery rate is observed and discontinuation of therapy is not always necessary. [13, 14].Accordingly, trastuzumab is often continued in patients deemed low risk while neurohormonal blockadeIs initiated usually with guideline directed medical therapy to improve LV function such as beta blockersand ACEi. While the authors report discontinuing or holding trastuzumab in 23 (13.5%) patients, they do not mention adjuvant treatment with neurohormonal blockade that might have influenced the results. Partial improvement of some parameters (LA εres and LVEF) at 12 months follow-up in patients who developed CTRCD raises the possibility that treatment with adjuvant therapy might be responsible for the beneficial changes. Another important limitation is the lack of additional echocardiographic parameters potentially related to LA function. A significant association exists between impaired LA strain and LV filling pressure (E/E′ ratio), pulmonary pressure (tricuspid regurgitation velocity), and RV systolic function (RVFAC) [15]. None of these parameters have been described in the manuscript.From a research perspective, future investigations should be mindful of the association between reduction in LV filling pressure and improvement in LA function as indicated by the improvement in LA strain and a more holistic approach should be used reporting echocardiographic parameters related toLV filling (i.e. E/E′ ratio, LA stiffness index or E/E′/LA reservoir strain). Although Strain and Strain Rate are increasingly used, deformation analysis of the LA offers unique challenges. Anatomic challenges as well as specific expertise and training required for accurate data acquisition and processing remain a significant impediment to a widespread clinical use. Advances in cardiac imaging in the field of speckle tracking echocardiography, including machine learning algorithms, may help overcome these obstacles and provide a more reliable and fast functional assessment of the LA.Despite the limitations the manuscript convincingly confirms previous reports that have demonstrated the added value of LA strain in the assessment of various pathologic conditions affecting LV function and reinforces the need for further work to establish its role in clinical applications such as risk stratification and decision-making strategies.BIBLIOGRAPHY1. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8.2. de Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013; 22(4):561-70.3. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29(4):277-314.4. Galderisi M, Esposito R, Sorrentino R, et al. Atrial Fibrillation, Cancer and Echocardiography. J Cardiovasc Echogr. 2020; 30(Suppl 1):S33-S7.5. Sarvari SI, Haugaa KH, Stokke TM, et al. Strain echocardiographic assessment of left atrial function predicts recurrence of atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2016; 17(6):660-7.6. Park H, Kim KH, Kim HY, et al. Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer. Cardiovasc Ultrasound. 2020; 18(1):28.7. Huynh QL, Kalam K, Iannaccone A,et al. Functional and Anatomic Responses of the Left Atrium to Change in Estimated Left Ventricular Filling Pressure. J Am Soc Echocardiogr. 2015; 28(12):1428-33.e1.8. Donal E, Behagel A, Feneon D. Value of left atrial strain: a highly promising field of investigation. Eur Heart J Cardiovasc Imaging. 2015; 16(4):356-7.9. M C Lassen, F Arya, T Biering-Sørensen, et al. Left Atrial Strain is Reduced Following Trastuzumab in Breast Cancer Patients. Echocardiography (InPress).10. Laufer-Perl M, Arias O, Dorfman SS, et al. Left Atrial Strain changes in patients with breast cancer during anthracycline therapy. Int J Cardiol.2021; 330:238-44.11. Tadic M, Genger M, Cuspidi C, et al. Phasic Left Atrial Function in Cancer Patients Before Initiation of Anti-Cancer Therapy. J Clin Med.2019; 8(4).12. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79(17):e263-e421.13. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006; 24(25):4107-15.14. Wang SY, Long JB, Hurria A, et al. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer ResTreat. 2014; 146(2):411-9.15. Santos AB, Roca GQ, Claggett B, et al. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016; 9(4):e002763.

Abstract Objective: We sought to evaluate the left atrial (LA) strain parameters of maintenance hemodialysis (MHD) patients before and after dialysis by two dimensional speckle tracking imaging (2D- STI), and to explore the effect of volume load change on LA function. Methods: 76 patients with end stage renal disease (ESRD) on hemodialysis (HD) were enrolled in the study protocol. The median duration of dialysis was 24.0 (7.5, 59.5) months. In addition, 30 healthy subjects were selected as control group. Comprehensive echocardiography was performed immediately before and after hemodialysis to compare the changes in left atrial function. Results: Regarding LA strain parameters in patients of pre-HD, the median (25th, 75th) LA reservoir, LA conduit, and LA contractile reserve were 28.0 (23.0, 34.5), -15.5 (-10.0, -21.5),-12.0 (-9.0, -16.0) respectively; the post-HD were 26.0 (21.0, 29.0), -12.0 (-9, -15.5), -12.5 (-9, -15.5) respectively; and controls were 43.0 (36.0, 48.0), -24.0 (-18.0, -32.0), -17.0 (-15.0, -22.0) respectively. The left atrial strain parameters before HD were lower than controls, the differences were statistically significant (P < 0.05). The reservoir function and conduit function of LA strain decreased after hemodialysis, the differences were statistically significant (P < 0.05). Regarding the contraction of LA, the differences between pre- and post-HD were not statistically significant (p > 0.05). Conclusion: New echocardiographic parameters, such as left atrial strain, can quantitatively evaluate the changes in left atrial function before and after hemodialysis in ESRD patients, which can provide valuable information for the overall cardiac evaluation in this specific population.

Introduction: Doppler-derived pulmonary pulse transit time (pPTT) is an auspicious hemodynamic marker in chronic pulmonary diseases. The aim is to compare four distinct pPTT measurements and its relation to right cardiac and pulmonary function. Methods: Prospectively, 22 chronic obstructive pulmonary disease (COPD) patients (one patient excluded) and 32 healthy subjects underwent repeated distinct pPTT measurements, one standard echocardiography and pulmonary function testing on the same day. pPTT was defined as the interval from the R or Q-wave in the ECG to the corresponding pulse wave Doppler peak late systolic (S2) or diastolic (D) pulmonary vein flow velocity (pPTT R-S , Q-S, R-D, Q-D). Reproducibility was evaluated using Bland-Altman analysis, coefficient of variation (COV), intraclass correlation coefficient (ICC) and power calculations. Coherence to right ventricle RV tissue und pulse wave Doppler velocities (RV E´, RV S´, RV A’, RV E, RV A, RV E/E‘, RV E/A (cm/s)), tricuspid annular plane systolic excursion (TAPSE), forced expiratory volume in 1 second (FEV1), vital capacity (FVC) predicted (%) and in (l) were analyzed. Results: There was no significant difference and no bias between pPTT measures (p range: 0.1 - 0.9). COV was in COPD 1.2 - 2.3%, in healthy subjects 1.0 % - 3.1 %. ICC ranged from 0.92 (COPD) to 0.96 (healthy subjects). In COPD significant correlations were found for pPTT R-S , Q-S and R-D with RV E‘, (all >ρ: 0.49, ρ: 0.49, ρ: -0.39, Conclusions: All pPTT measures were highly reproducible and affected by diastolic RV performance. Defining Q as starting point seems clinically advantageous considering electromechanical desynchrony in patients with conduction disorders.

Patent foramen oval and ESUS in cryptogenic stroke: still a complex puzzleDiana-Elena Iov1,2, MD, Mariana Floria1,3*, MD, PhD, Daniela Maria Tanase1,3, MD, PhD1Faculty of Medicine, Department of Internal Medicine, University of Medicine and Pharmacy ”Grigore T. Popa”, 700111 Iasi, Romania.2Emergency Clinical Hospital ”Saint Spiridon”, Institute of Gastroenterology and Hepatology, 700111 Iasi, Romania.3Emergency Clinical Hospital ”Saint Spiridon”, Internal Medicine Clinic, 700111 Iasi, Romania.Running title: Patent foramen oval related stroke

Objective: This study aimed to analyze myocardial work in patients with atrial fibrillation (AF) using a non-invasive pressure strain loop (PSL) technique to provide a basis for the quantitative assessment of left ventricular （LV） systolic function. Methods: LV myocardial work of 107 AF patients and 55 healthy individuals was assessed by the non-invasive PSL and then compared. Results: Global longitudinal strain (GLS) in absolute values, global work index (GWI), global constructive work (GCW), and global work efficiency (GWE) were significantly lower in the AF group than control group, whereas peak strain dispersion (PSD) and global wasted work (GWW) were significantly higher ( P<0.05). Further subdivision according to the AF type revealed that, compared with the controls, GLS in absolute values and GWE decreased significantly; PSD and GWW increased significantly in the paroxysmal AF group ( P<0.05). Compared to paroxysmal AF, persistent AF induced a further decrease in absolute GLS and GWE and a further increase in GWW ( P<0.05) . Multiple linear regression analysis showed that GWI and GCW were associated with systolic blood pressure. GWW was associated with types of AF and left atrial volume index (LAVI). GWE was correlated with age, types of AF, disease duration, and LAVI. Receiver operating characteristic curve analysis showed that the area under the curve predicting myocardial injury was higher for GWE and GWW than for GLS. Conclusions: Non-invasive PSL can quantitatively assess LV systolic function in patients with different kinds of AF and detect early subclinical myocardial injury in patients with paroxysmal AF. Systolic blood pressure, type of AF, LVAI, disease duration, and age may be associated with myocardial injury in patients with AF.

Aim: To test the feasibility and accuracy of a new attention-based deep learning (DL) method for right ventricular (RV) quantification using 2D echocardiography (2DE) with cardiac magnetic resonance imaging (CMR) as reference. Methods and results: We retrospectively analyzed images from 50 adult patients (median age 51, interquartile range 32-62 42% women) who had undergone CMR within 1 month of 2DE. RV planimetry of the myocardial border was performed in end-diastole (ED) and end-systole (ES) for 8 standardized 2DE RV views with calculation of areas. The DL model comprised a Feature Tokenizer module and a stack of Transformer layers. Age, gender and calculated areas were used as inputs, and the output was RV volume in ED/ES. The dataset was randomly split into training, validation and testing subsets (35, 5 and 10 patients respectively). Mean RVEDV, RVESV and RV ejection fraction (EF) were 163±70ml, 82±42ml and 51±8% respectively without differences among the subsets. The proposed method achieved good prediction of RV volumes (R 2=0.953, absolute percentage error [APE]=9.75±6.23%) and RVEF (APE=7.24±4.55%). Per CMR, there was 1 patient with RV dilatation and 3 with RV dysfunction in the testing dataset. The DL model detected RV dilatation in 1/1 case and RV dysfunction in 4/3 cases. Conclusions: An attention-based DL method for 2DE RV quantification showed feasibility and promising accuracy. The method requires validation in larger cohorts with wider range of RV size and function. Further research will focus on the reduction of the number of required 2DE to make the method clinically applicable.

Dextrocardia is a cardiac positional anomaly in which the heart is located in right hemithorax with base-to-apex axis directed to the right and caudad. A number of congenital heart defects have been reported with dextrocardia, including VSD, PDA, ASD, TOF, pentalogy of Fallot, infundubular PS, transposition and pseudotruncus and total anomalous pulmonary venous return. We will share a patient with severe TR due to tricuspid valve commissural prolapse. A 42-year-old female patient was admitted to our clinic with the complaint of dyspnea. Transthoracic echocardiography revealed dextrocardia and severe TR consisting of two separate regurgitation jets. Contrast echocardiography performed due to dilatation of the coronary sinüs, did not show persistent left superior vena cava, and no right-to-left shunt was observed. Transesophageal echocardiography showed a prolapse in the commissure where the tricuspid anterior and septal leaflets meet, and a severe eccentric regurgitation jet with an area of vena contracta 0.75cm2 in the 3D MPR was observed. A moderate regurgitation jet was also seen from the coaptation line of all three leaflets. Commussural prolapse and regurgitation jet revealed in detail by 3D imaging. No significant pathology was detected in the other valves except mild insufficiency. Right heart catheterization and tricuspid valve surgery were planned for the patient with normal right heart functions. Although it is known that there are many congenital pathologies accompanying dextrocardia, we are happy to share our experience with you as the first case to report the coexistence of primary tricuspid valve disease and commusural prolapse with 3D detailed imaging.

ABSTRACT Maternal hyperoxygenation (MH) has been studied as a diagnostic tool to evaluate pulmonary vasculature and as a treatment option to improve the growth of fetal left heart in fetuses with left-sided cardiac defects. Chronic maternal hyperoxygenation (CMH) therapy leads to an improvement in fetal pulmonary blood flow resulting in an enhanced venous return to the left heart with increased gestational age. With this manipulation it is anticipated to augment blood flow directed remodeling of the left heart structures and to improve left heart growth spanning from the mitral valve to the aortic isthmus. However, there are concerns about CMH therapy with regard to fetal complications with growth restriction and fetal brain development. Now, with two successful cases we try to discuss this fetal treatment option and related concerns.

A 59-year-old male was incidentally diagnosed with a left atrial mitral valve chordae involving the junction of the A1 and A2 mitral valve leaflets and resulting in moderate mitral regurgitation. The recognition of this extremely rare congenital malformation prevented over diagnosis and overtreatment.

A giant coronary artery aneurysm (GCAA) concurrent with coronary artery fistula is a rare condition, and it becomes even more unusual when combined with a single coronary artery (SCA) anomaly. Here we report such an extremely rare case, who is a 35-year-old woman presenting with severe chest distress. A GCAA with fistula to the right ventricle was noted, occurring in a single coronary artery, diagnosed by multimodality cardiovascular imaging techniques. Both GCAA and coronary artery fistula can cause severe cardiac complications, which jeopardize life. While an SCA is mostly asymptomatic, it may also lead to sudden cardiac death as well. Therefore, surgical intervention was recommended. We chose a novel thrombus-inducing strategy to eliminate the GCAA and repair the fistula. Symptoms were relieved after the surgery, and the patient remained asymptomatic over 8 months of follow-up.

Objective: To assess the accuracy of prenatal echocardiography in defining pulmonary vasculature in pulmonary atresia with VSD (PAVSD). The second aim is to compare the perinatal and postnatal outcomes of different pulmonary blood supply types. Design:The cases prenatally diagnosed with PAVSD between January 2017- October 2022 in a single tertiary fetal medicine center were identified on the electronic database. Fetal echocardiography reports and images were reviewed retrospectively. Postnatal outcomes and images were acquired from the hospital records of relevant pediatric cardiology and cardiovascular surgery clinics. Fetal echocardiography results were compared with postnatal results. Perinatal and postnatal outcomes were compared between the pulmonary vascular supply types. Results: Among the 24 PAVSD cases, six were diagnosed with major aortopulmonary collateral arteries (MAPCA) dependent, eleven were diagnosed with ductus arteriosus (DA) dependent pulmonary vascular supply, and seven were diagnosed with double pulmonary supply (MAPCA + DA) on prenatal echocardiography. Seventeen cases were live-born and have undergone postnatal investigations. Fetal echocardiography was 88.2% accurate about the type of pulmonary vascular supply. The accuracy of fetal echocardiography regarding pulmonary vascular anatomy was 82.3%. Four cases were demised before surgical interventions. Postoperative survival was 69.2%. Mortality and postoperative survival did not differ between pulmonary supply groups. Survival was disrupted with extracardiac anomalies. The need for early surgical interventions was significantly higher in the DA group. Conclusion:The anatomy of pulmonary vascularization in PAVSD can be defined precisely on fetal echocardiography. The source of pulmonary blood supply does not impact postnatal short-term outcomes significantly; however, it affects the postnatal management. The associated anomalies highly contribute to postnatal mortality. Therefore, MAPCAs, the anatomy of the pulmonary arteries, and accompanying abnormalities should be intensely searched on fetal ultrasonography.

Double orifice mitral valve is a rare congenital anomaly that is often associated with other congenital cardiac abnormalities. Patients may present with valvular dysfunction or may be asymptomatic and have an incidental diagnosis of double outlet mitral valve. Whether symptoms due to this pathology are present or not, it is important to accurately characterize this lesion. 3-dimensional imaging is a powerful diagnostic modality for diagnosing and characterizing lesions such as this as highlighted in this case image series.

A 46-year-old woman underwent pericardiocentesis and pericardial window for recurrent pericardial effusion. She presented 17 months later with signs and symptoms consistent with constrictive pericarditis. Cardiac magnetic resonance imaging revealed an infiltrative mass surrounding the pericardium. A transcutaneous core needle biopsy of the pericardium confirmed the diagnosis of pericardial mesothelioma.

A 32-year-old female patient presented with palpitations and chest discomfort. The patient had a history of pericardiotomy due to pericardial effusion. Multimodal imaging, including echocardiography, cardiac magnetic resonance (CMR), and coronary computed tomography angiography (CCTA) were used showing a pericardial cyst as the cause of the symptoms. Furthermore its location and potential complications were accurately defined. The patient underwent successful surgical resection of the cyst, and histopathological analysis confirmed a bronchogenic cyst, a very rare congenital malformation. The article discusses the rarity of bronchogenic cysts in the pericardium and the importance of accurate diagnosis and appropriate treatment.

Introduction and objectives：Traditional transcatheter closure of atrial septal defect (ASD) via the femoral vein carries risk of radiation damage. Transcutaneous closure of ASD under echocardiography guidance avoids radiation exposure and can be gradually applied. An alternative is to transcutaneous closure of ASD trans-jugular with an adjustable curved sheath under echocardiography guidance. Methods: We retrospectively studied all cases of trans-jugular transcutaneous closure of ASD with an adjustable curved sheath under echocardiography guidance in the Heart Center of Henan Province People’s Hospital between 2016 and December 2022. Results: 156 patients were included, 74 males and 82 females. Mean age was 6.9 ± 7.4 years and weight 23.7 ± 14.6 kg. Mean sizes of the ASD and occluder were (9.7 ± 4.7) mm and (14.1 ± 5.7) mm. The mean operation time was (49.6 ± 29.2) min. No complications such as atrioventricular block, reoperation, or pericardial effusion occurred. There are 3 patients had a residual shunt. All patients were followed-up for (38.7 ± 11.0)months. The 3 patients with residual shunt had self-closed at the 3-6-12months follow-up. There was no complication at follow-up. Conclusion: Trans-jugular transcutaneous closure of ASD with adjustable curved sheath under echocardiography guidance is safe, effective and minimally invasive.

Effective treatment, but also proper diagnosis of cardiovascular diseases, remains a major challenge in everyday practice. A quick, safe, and economically acceptable non-invasive procedure should play a leading role in cardiovascular risk assessment before invasive diagnostics is performed. The staging of subclinical atherosclerosis may help in further clinical decisions. Safe, widely available, and relatively inexpensive, ultrasonography is a promising examination that should find wider application in clinical practice. The latest ESC guidelines emphasize the usefulness of carotid ultrasound in the diagnosis of coronary artery disease (CAD) and subclinical assessment of atherosclerosis, which help to determine the level of cardiovascular risk. Ultrasound examination of peripheral arteries, especially superficial vessels such as the femoral arteries, is quite easy, quick, and accurate. Other vascular beds, such as iliac and renal, are more demanding to examine, but can also provide valuable information. This review summarizes important studies comparing the severity of atherosclerosis in ultrasound-visible vascular beds in patients with established CAD. We especially emphasize the benefits of the combined assessment of atherosclerosis features, which were characterized by high sensitivity and specificity in the diagnosis of CAD and other serious cardiovascular diseases.